Searched for
OPHTHALMOLOGY MARKET GROWTH
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
Volatility as opportunity, depends on framework of mind: 5 mid-caps from different sectors with upside potential of up to 31%The Indian stock market is no longer correcting only because of sentiment. It is now adjusting to the possibility of weaker numbers in the ...
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsFor the next few weeks, what needs to be watched is market breadth. And also look at which sectors are leading the rally. Why? Because, at ...
Market will be volatile, look for an alternative solution: 5 large-caps from different sectors with upside potential of up to 30%A fall in crude oil prices can trigger a relief rally, which in fact it did in early trade on Thursday. But there is another reality as wel...
Time to take the first step to become a contrarian? 4 mid-cap stocks from different sectors with upside potential up to 21%As the risk created by the US-Iran war keeps crude oil prices elevated, the list of stocks where investors can deploy fresh money with comf...
Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
For investors with patience, experience, and anxiety appetite: 5 stocks from different sectors with upside potential of up to 21%For the last five years, the theme on the street has mostly been: Buy today, expect comfort tomorrow. But some of the better wealth-creatin...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%In these times of geopolitical stress, how will things pan out for the Indian market? Will it be a standalone underperformer? Or is it just...